Pluri Inc. (NASDAQ: PLUR, TASE: PLUR) announced that its majority-owned subsidiary, Ever After Foods Ltd. (EAF), has acquired Fishway BV, a Belgium-based biotechnology company specializing in aquatic cell biology and animal-component-free media development for the cultivated-protein industry.

The acquisition adds Fishway's scientific capabilities in aquatic cell biology to EAF's existing bioprocess and manufacturing platform. The deal also gives EAF a physical presence in Belgium, expanding its European operations.

In connection with the acquisition, EAF secured an additional $2 million strategic investment through a simple agreement for future equity (SAFE Agreement) to support platform development and commercialization activities.

Eyal Rosenthal, CEO of Ever After Foods, said the acquisition adds "strong capabilities in aquatic cell biology and animal-component-free media that complement Ever After Foods' production platform and expand the range of applications we can support."

Yaky Yanay, President and CEO of Pluri, said Fishway "brings complementary science, talent and a European base to EAF," describing the move as "a focused strategic step that strengthens the platform."

EAF describes itself as an open manufacturing platform developer for the cultivated-protein industry, integrating biology, media, bioprocess engineering, and advanced manufacturing. Pluri, headquartered in Haifa, Israel, is a biotechnology company focused on 3D cell-expansion technology across therapeutics, regenerative aesthetics, and agri-food tech.